Mon 06 September 2021:
According to a new analysis, wealthy countries could have a surplus of more than one billion COVID-19 vaccine doses accessible by the end of the year that are not designated as donations to poorer countries.
Vaccine stock in Western countries has reached 500 million doses this month, with 360 million not earmarked for donations, according to new research by data analytics firm Airfinity. By the end of the year, these countries will have a potential of 1.2 billion surplus vaccine shots, with the overwhelming majority – 1.06 billion – not marked for donations, it said.
Vaccine inequality has been denounced by many prominent health figures and officials. COVAX, the UN-backed global vaccine-sharing scheme, had initially aimed to provide two billion vaccine doses to people in 190 countries this year – including 92 lower-income countries – ensuring at least 20 percent of populations are vaccinated.
However, the wealthy countries’ deals with vaccine manufacturers have limited the vaccines available to COVAX and led to vaccine hoarding.
Noting that more than 5 billion vaccines had been administered worldwide, he said almost 75 percent of those doses had been administered in just 10 countries. Vaccination coverage in Africa was just 2 percent, he said.
Ghebreyesus was echoed by John Nkengasong, the head of the Africa Centers for Disease Control and Prevention (Africa CDC), who described the vaccine rollout on the continent as a “total disappointment“.
On Sunday, former British Prime Minister Gordon Brown accused rich countries of committing a “moral outrage” by stockpiling COVID-19 doses while poor countries were struggling to get supplies.
Brown, who is a United Nations special envoy, called on US President Joe Biden and other Group of Seven leaders to urgently ship vaccines from warehouses in America and Europe to Africa.
The stockpiling has also delayed dose-sharing by G7 countries with Africa and low-income countries, Brown said.
Ghebreyesus called on the G20 to swap near-term delivery schedules with COVAX, fulfilling dose-sharing promises by the end of this month, and facilitating the sharing of technology, know-how and intellectual property to support regional vaccine manufacturing.
